杭州沐源生物医药科技

Hangzhou Muyuan Biopharmaceutical Technology (Muyuan Bio) is a China-based biotechnology company specializing in the discovery and development of innovative small molecule drugs, with a primary focus on targeted protein degradation (TPD) technologies. The company leverages its proprietary platform to develop molecular glues and PROTACs aimed at treating refractory cancers and other diseases with high unmet medical needs. Founded by industry veterans, Muyuan Bio integrates computational chemistry and structural biology to accelerate the identification of novel undruggable targets. The company is currently in the pre-clinical stage, advancing a pipeline of candidates targeting key oncogenic drivers such as GSPT1. Muyuan Bio is headquartered in Hangzhou and has received significant early-stage funding from prominent venture capital firms.